Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Dialysis Clinic, Inc. | INDUSTRY |
| InBody | UNKNOWN |
Not provided
Not provided
Not provided
This is a pilot randomized clinical trial in which patients treated with 3X per weekly conventional hemodialysis will be treated to a dialysate sodium 135 mEq/L vs. 138 mEq/L and followed for safety and tolerability, effects on BP and volume.
This is a pilot randomized clinical trial in which hypertensive hemodialysis patients will be randomized to a low dialysate sodium (Na) of 135 mEq/L or a standard dialysate Na of 138 mEq/L. Patients will be randomized 2:1 to the low arm. Dialysate Na will be lowered 1 mEq/L every 2 weeks, as tolerated. Tolerance will be assessed by symptoms, intradialytic hypotension (IDH) episodes (systolic BP <90 or intervention for symptoms or BP drop during dialysis), achievement of dry weight. The trial will last for 6 to 12 months, for an individual, depending on when they entered the trial. The primary outcome is feasibility and safety of using the lower dialysate sodium which is assessed by symptoms during or immediately after dialysis, intradialytic hypotension episodes and the frequency of emergency room visits and hospitalizations. Several secondary outcomes will be measured including blood pressure prior to dialysis and at home, change in plasma Na over time, dry weight, post-dialysis weight, interdialytic weight change, symptoms of thirst and dry mouth, self-reported dialysis recovery time, relative blood volume change during a single treatment (via 'Critline') and, in patients without an implanted electronic device, extraceullular fluid volume (via bioimpedance).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control Group | No Intervention | ||
| Intervention Group | Experimental | Intervention group will dialyze with dialysate Na 135 mEq/L. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dialysate Sodium Lowering | Other | Dialysate sodium is lowered until nadir sodium level is reached. Participant dialyzes at this sodium level until end of follow-up. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of Intradialytic Hypotension | IDH is determined by review of blood pressures (measured every 30 minutes during dialysis), symptoms (recorded by the nurse during the dialysis treatment and reviewed at Q2 weekly face to face visits by the study team) and the need for intervention (targeted ultrafiltration goal was reduced; treatment was terminated early or saline given for intradialytic hypotension. IDH is defined by any 1 (or more of the following) 1) lowest intradialytic Systolic BP <90 mm Hg or 2) intradialytic symptoms (cramps, lightheadedness, nausea +/-vomiting, diaphoresis, loss of consciousness or seizure) OR 3) intervention performed for symptoms of IDH or lowest intradialytic BP <90 mm Hg. The # IDH events (meeting 1 or more of the 3 criteria above) per 100 treatments will be compared across treatment arms. | Baseline period through study completion, an average of 6 months |
| Dialysis Dysequilibrium (Safety) | Ascertained via self-report on a questionnaire that asks about the frequency of symptoms suggestive of DD occurring during or immediately after dialysis. The symptoms are: headache, nausea +/- vomiting, confusion, drowsiness, muscle twitching, blurred vision. There are 5 response options ranging from never through to very often for each question. The questionnaire is administered at baseline, at 6 weeks, and Q3 months thereafter. The change in frequency of each symptom will be compared across arms. | Baseline period through study completion, an average of 6 months |
| Frequency of ER visits and hospitalizations (safety) | The frequency of ER visits and hospitalizations will be ascertained at Q2 weekly study visits. The # of events per time at risk will be compared across treatment arms. | Baseline through study completion |
| Frequency of patients treated to a dialysate Na 135 mEq/L at end of study (feasibility) | Among those assigned to Dialysate Na 135 mEq/l as the denominator, the # actually continuing to dialyze at this level during the last two weeks of study follow-up. |
| Measure | Description | Time Frame |
|---|---|---|
| Pre- and post-dialysis Plasma Sodium | Taken from lab draws immediately before and after start of dialysis treatment. | Baseline period through study completion, an average of 6 months |
| Dialysate Sodium |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dana Miskulin, MD | Tufts Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| DCI Boston | Boston | Massachusetts | 02111 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39498822 | Derived | Marshall MR, Wang MY, Vandal AC, Dunlop JL. Low dialysate sodium levels for chronic haemodialysis. Cochrane Database Syst Rev. 2024 Nov 5;11(11):CD011204. doi: 10.1002/14651858.CD011204.pub3. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D004487 | Edema |
| C535731 | Dysequilibrium syndrome |
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Last 2 weeks of Follow-up |
Sample of dialysate sodium taken 30 minutes after start of dialysis treatment.
| Baseline period through study completion, an average of 6 months |
| Relative Blood Volume | Determined using CRIT LINE III monitors. | Baseline period through study completion, an average of 6 months |
| Bioimpedance Analysis | Water volume and bioimpedance results will be determined using InBodyS10 device. | Baseline period through study completion, an average of 6 months |
| Interdialytic Weight Gain | Determined by analysis of treatment sheets. | Baseline period through study completion, an average of 6 months |
| Post Dialysis Weight | Determined by analysis of treatment sheets. | Baseline period through study completion, an average of 6 months |
| Estimated Dry Weight | Determined by analysis of treatment sheets. | Baseline period through study completion, an average of 6 months |
| Pre- and Post-dialysis Sitting Blood Pressure | Determined by analysis of treatment sheets. | Baseline period through study completion, an average of 6 months |
| Home Blood Pressure Monitoring | Participants will use a LifeSource blood pressure monitor to measure their blood pressure weekly at home. | Baseline period through study completion, an average of 6 months |
| Sodium Loss during Dialysis | Calculated according to the formula: pre-dialysis total body Na - post-dialysis total body Na, where the volume of distribution in the extracellular space is estimated as 0.58*target weight. | Baseline period through study completion, an average of 6 months |
| Thirst and Xerostomia | Thirst and Xerostomia will be measured via validated, self-administered questionnaires, the 'Dialysis Thirst Inventory' and the 'Xerostomia Inventory' , respectively (BotsCP et al, Kidney International:66; 2004). Change in each inventory score from baseline to the end of the study will be compared by treatment arm. | Baseline through study completion, an average of 6 months |